Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 15, Pages 3912
Publisher
MDPI AG
Online
2021-08-03
DOI
10.3390/cancers13153912
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma
- (2019) Fang Bao et al. CANCER GENE THERAPY
- Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis
- (2019) Wen-Liang Yu et al. Cancers
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
- (2019) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Neurological toxicities associated with chimeric antigen receptor T-cell therapy
- (2019) Daniel B Rubin et al. BRAIN
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells
- (2019) Kevin A. Hay et al. BLOOD
- Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
- (2019) Huiwen Jiang et al. ANNALS OF HEMATOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
- (2019) Tao Wang et al. JOURNAL OF IMMUNOTHERAPY
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy
- (2019) Alexandre V. Hirayama et al. BLOOD
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial
- (2019) Huiwen Jiang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
- (2019) Zixun Yan et al. CLINICAL CANCER RESEARCH
- Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
- (2019) Futian Ma et al. HEMATOLOGICAL ONCOLOGY
- Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
- (2019) Yaqing Cao et al. Frontiers in Oncology
- Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
- (2019) Julia Ruark et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL
- (2019) Kevin J. Curran et al. BLOOD
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
- (2019) Hidefumi Hiramatsu et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
- (2019) Xin Jin et al. LEUKEMIA
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
- (2019) Noelle V. Frey et al. JOURNAL OF CLINICAL ONCOLOGY
- CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study
- (2018) Guoqing Wei et al. ANNALS OF HEMATOLOGY
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL
- (2018) John Rossi et al. BLOOD
- Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma
- (2018) Jakub Svoboda et al. BLOOD
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
- (2018) Jianyu Weng et al. Journal of Hematology & Oncology
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
- (2018) Elad Jacoby et al. AMERICAN JOURNAL OF HEMATOLOGY
- Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy
- (2018) Haneen Shalabi et al. JOURNAL OF IMMUNOTHERAPY
- A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Yongxian Hu et al. BONE MARROW TRANSPLANTATION
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
- (2018) Susanne H. Baumeister et al. Cancer Immunology Research
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
- (2017) J Pan et al. LEUKEMIA
- Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia
- (2017) C Rossig et al. LEUKEMIA
- Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
- (2017) Chengcheng Zhang et al. MOLECULAR THERAPY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
- (2015) Hanren Dai et al. OncoImmunology
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
- (2012) B. G. Till et al. BLOOD
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More